Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Martin JE, Sheaff MT. Renal ageing. J Pathol. 2007;211:198–205.
Harris RC, Neilson EG. Toward a unified theory of renal progression. Annu Rev Med. 2006;57:365–80.
Percy CJ, Power D, Gobe GC. Renal ageing: changes in the cellular mechanism of energy metabolism and oxidant handling. Nephrology (Carlton). 2008;13:147–52.
St Peter WL. Chronic kidney disease and medicare. J Manag Care Pharm. 2007;13(Suppl D):S13–8.
Cass A, Cunningham J, Snelling P, Wang Z, Hoy W. Exploring the pathways leading from disadvantage to end-stage renal disease for indigenous Australians. Soc Sci Med. 2004;58:767–85.
Pat B, Hughson MD, Nicol JL, Hoy WE, Gobe GC. A comparison of pathomolecular markers of fibrosis and morphology in kidney from autopsies of African Americans and whites. Virchows Arch. 2007;450:41–50.
Hughson MD, Gobe GC, Hoy WE, Manning Jr RD, Douglas-Denton R, Bertram JF. Associations of glomerular number and birth weight with clinicopathological features of African Americans and whites. Am J Kidney Dis. 2008;52:18–28.
Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol. 2003;93:P3–13.
Masajtis-Zagajewska A, Nowicki M. Influence of dual blockade of the renin-angiotensin system on thirst in hemodialysis patients. Nephron Clin Pract. 2009;112:c242–7.
Lane A, Johnson DW, Pat B, et al. Interacting roles of myofibroblasts, apoptosis and fibrogenic growth factors in the pathogenesis of renal tubulo-interstitial fibrosis. Growth Factors. 2002;20:109–19.
Wojcikowski K, Johnson DW, Gobe G. Medicinal herbal extracts – renal friend or foe? Part two: herbal extracts with potential renal benefits. Nephrology (Carlton). 2004;9:400–5.
Tylicki L, Puttinger H, Rutkowski P, Rutkowski B, Horl WH. Smoking as a risk factor for renal injury in essential hypertension. Nephron Clin Pract. 2006;103(4):c121–8.
Lamacchia O, Pinnelli S, Camarchio D, et al. Waist-to-height ratio is the best anthropometric index in association with adverse cardiorenal outcomes in type 2 diabetes mellitus patients. Am J Nephrol. 2009;29:615–9.
Lu Q, Cheng LT, Wang T, et al. Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients. J Ren Nutr. 2008;18:495–502.
Whaley-Connell A, Pavey BS, Chaudhary K, Saab G, Sowers JR. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Ther Adv Cardiovasc Dis. 2007;1:27–35.
Hall AM, Unwin RJ. The not so ‘mighty chondrion’: emergence of renal diseases due to mitochondrial dysfunction. Nephron Physiol. 2007;105:1–10.
Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot-Leclercq MP. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis. 2008;13:11–32.
Nordberg M. Environmental exposure and preventive measures in Sweden and EU. Biometals. 2004;17:589–92.
Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol. 2010;105(1 Suppl):30A–5.
Komers R. What is the role of renin inhibition in the treatment of diabetic kidney disease? Curr Diab Rep. 2009;9:447–52.
Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes. 2007;115:69–84.
González-Périz A, Horrillo R, Ferré N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 2009;23:1946–57.
Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond). 2009;116:87–98.
Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role. Nat Rev Nephrol. 2009;5:375–83.
Fellström B, Holdaas H, Jardine AG, et al. Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin. 2009;25:271–85.
Fathi R, Isbel N, Short L, et al. The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis. 2004;43:45–52.
Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation. 2003;107:2646–52.
Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol. 1999;10:2177–84.
Percy C, Pat B, Poronnik P, Gobe G. Role of oxidative stress in age-associated chronic kidney pathologies. Adv Chronic Kidney Dis. 2005;12:78–83.
Thaha M, Widodo, Pranawa W, Yogiantoro M, Tomino Y. Intravenous N-acetyl-cysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Clin Nephrol. 2008;69:24–32.
Prasad K. Vitamin E does not regress hypercholesterolemic atherosclerosis. J Cardiovasc Pharmacol Ther. 2009;14:231–41.
Machlin LJ, Gabriel E. Kinetics of tissue alpha-tocopherol uptake and depletion following administration of high levels of vitamin E. Ann NY Acad Sci. 1982;393:48–60.
Machlin LJ. Clinical uses of vitamin E. Acta Vitaminol Enzymol. 1985;7(Suppl):33–43.
Baker H, Frank B, Feingold S, de Angelis S. Plasma tocopherol in man at various times after ingesting free or acetylated tocopherol. Nutr Rep Internat. 1980;21:531–6.
Giray B, Kan E, Bali M, Hincal F, Basaran N. The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients. Clin Chim Acta. 2003;338:91–8.
Islam KN, O’Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis. 2000;150:217–24.
Akiyama S, Inagaki M, Tsuji M, et al. Comparison of effect of vitamin E-coated dialyzer and oral vitamin E on hemodialysis-induced Cu/Zn-superoxide dismutase. Am J Nephrol. 2005;25:500–6.
Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842–57.
Blatt DH, Pryor WA. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:150–1.
Hemila H. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:151–2.
Krishnan K, Campbell S, Stone WL. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:151. author reply 156–158.
Marras C, Lang AE, Oakes D, et al. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:152–3.
Lim WS, Liscic R, Xiong C, Morris JC. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:152.
DeZee KJ, Shimeall W, Douglas K, Jackson JL. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:153–4. author reply 156–158.
Meydani SN, Lau J, Dallal GE, Meydani M. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:153. author reply 156–158.
Possolo AM. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:154. author reply 156–158.
Baggott JE. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:155–6. author reply 156–158.
Carter T. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:155. author reply 156–158.
Jialal I, Devaraj S. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:155. author reply 156–158.
Huang HY, Appel LJ. Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans. J Nutr. 2003;133:3137–40.
Corrigan Jr JJ, Marcus FI. Coagulopathy associated with vitamin E ingestion. JAMA. 1974;230:1300–1.
Dowd P, Zheng ZB. On the mechanism of the anticlotting action of vitamin E quinone. Proc Natl Acad Sci USA. 1995;92:8171–5.
Megavitamin E. supplementation and vitamin K-dependent carboxylation. Nutr Rev. 1983;41:268–70.
Ikizler TA. Nutrition, inflammation and chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17:162–7.
Fetterman Jr JW, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm. 2009;66:1169–79.
Panzetta O, Cominacini L, Garbin U, et al. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effects of fish oil and vitamin E administration. Clin Nephrol. 1995;44:303–9.
Barbosa V, Miles E, Calhau C, Lafuente E, Calder P. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled trial. Crit Care. 2010;14:R5. doi:10.1186/cc8844.
Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989;320:265–71.
Hughes DA, Pinder AC, Piper Z, Johnson IT, Lund EK. Fish oil supplementation inhibits the expression of major histocompatibility complex class II molecules and adhesion molecules on human monocytes. Am J Clin Nutr. 1996;63:267–72.
Fassett R, Gobe G, Peake J, Coombes J. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis. 2010;56:728–42.
Liani M, Salvati F, Golato M, et al. Immunological effects of fish oil on patients with end-stage renal disease. Nephron. 1995;69:86–90.
Mayer K, Fegbeutel C, Hattar K, et al. Omega-3 versus omega-6 lipid emulsions exert differential influence on neutrophils in septic shock: impact of fatty acids and lipid mediator generation. Intensive Care Med. 2003;29:1472–81.
Tappt L, Berger M, Schwartz J, et al. Metabolic effects of parenteral nutrition enriched with n-3 polyunsaturated fatty acids in critically ill patients. Clin Nutr. 2006;25:588–95.
Blackhall ML, Coombes JS, Fassett R. The relationship between antioxidant supplements and oxidative stress in renal transplant recipients: a review. ASAIO J. 2004;50:451–7.
Wojcikowski K, Stevenson L, Leach D, Wohlmuth H, Gobe G. Antioxidant capacity of 55 medicinal herbs traditionally used to treat the urinary system: a comparison using a sequential three-solvent extraction process. J Altern Complement Med. 2007;13:103–9.
Huang D, Ou B, Prior RL. The chemistry behind antioxidant capacity assays. J Agric Food Chem. 2005;53:1841–56.
Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53:4290–302.
Saenger AK, Laha TJ, Edenfield MJ, Sadrzadeh SM. Quantification of urinary 8-iso-PGF2alpha using liquid chromatography-tandem mass spectrometry and association with elevated troponin levels. Clin Biochem. 2007;40:1297–304.
Cottone S, Mulè G, Guarneri M, et al. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant. 2009;24:497–503.
Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE): randomized placebo-controlled trial. Lancet. 2000;356:1213–8.
Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154–60.
Procopio A, Alcaro S, Nardi M, et al. Synthesis, biological evaluation, and molecular modeling of oleuropein and its semisynthetic derivatives as cyclooxygenase inhibitors. J Agric Food Chem. 2009;57:11161–7.
Sato H, Genet C, Strehle A, et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun. 2007;362:793–8.
Zhong L, Furne JK, Levitt MD. An extract of black, green, and mulberry teas causes malabsorption of carbohydrate but not of triacylglycerol in healthy volunteers. Am J Clin Nutr. 2006;84:551–5.
Kamgar M, Zaldivar F, Vaziri ND, Pahl MV. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. J Natl Med Assoc. 2009;101:336–44.
Wojcikowski K, Johnson DW, Gobe G. Medicinal herbal extracts renal friend or foe? Part one: the toxicities of medicinal herbs. Nephrology (Carlton). 2004;9:313–8.
Gabardi S, Munz K, Ulbricht C. A review of dietary supplement-induced renal dysfunction. Clin J Am Soc Nephrol. 2007;2:757–65.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Gobe, G.C., Fassett, R.G., Coombes, J.S. (2011). Bioactive Nutritional Supplements for Chronic Kidney Disease: Potential Cost Benefits. In: Gerald, J., Watson, R., Preedy, V. (eds) Nutrients, Dietary Supplements, and Nutriceuticals. Nutrition and Health. Humana Press. https://doi.org/10.1007/978-1-60761-308-4_19
Download citation
DOI: https://doi.org/10.1007/978-1-60761-308-4_19
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-307-7
Online ISBN: 978-1-60761-308-4
eBook Packages: MedicineMedicine (R0)